ELIXIRGEN

pharmaceutical preparations and substances for the treatment of telomere-shortening diseases (e.g., dyskeratosis congenita, Fanconi anemia, idiopathic and pulmonary fibrosis), karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and pseudobulbar palsy), muscular diseases (e.g., Muscular atrophies, muscular growth, myopathy diseases, muscular disorders, muscular dystrophy, myositis, neuromuscular diseases, and sarcopenia), diseases related to the brain, diseases related to the spine, cancer; chemicals and chemical preparations for medical and pharmaceutical purposes for telomere-shortening diseases (e.g., dyskeratosis congenita, and Fanconi anemia), idiopathic pulmonary fibrosis, karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and pseudobulbar palsy), muscular diseases (e.g., Muscular atrophies, muscular growth, myopathy diseases, muscular disorders, muscular dystrophy, myositis, neuromuscular diseases, and sarcopenia), diseases related to the brain, diseases related to the spine, and cancers

Development of pharmaceutical products for others; product quality testing and evaluation for others; research and development of pharmaceutical products for others; research and development of medical products for others